(Incorporated in Delaware)

Note: The SEC filing calls this deal the U.S. initial public offering of Anteris Technologies Global Corp. Some might say that the offering reads like an uplisting – a public offering – because ATL’s ordinary shares were admitted for official quotation on the Australian Securities Exchange (the ASX) on March 24, 2004 – more than 12.5 years ago.- as of the Dec. 9, 2024, date on the S-1/A filing disclosing the deal’s terms. The offering price is the U.S. dollar equivalent of the stock’s closing price on Dec. 5, 2024, on the ASX, according to the prospectus. 

Note: ATL is an Australian public company originally registered in Western Australia, Australia that was incorporated in 1999. ATL’s ordinary shares were admitted for official quotation on the ASX on March 24, 2004.

We intend to use the net proceeds of the IPO to develop our DurAVR transcatheter heart valve (“DurAVR^® THV”) and for the preparation and enrollment of a randomized global pivotal study of DurAVR^® THV to treat severe aortic stenosis, with the remaining for working capital and other general corporate purposes determined from time to time, including the repayment of amounts owed under our convertible note facility.

Following the Offering, ATGC intends to list its CHESS Depositary Interests (“CDIs”) (representing underlying shares of Common Stock on a 1 CDI-for-1 share of Common Stock basis) on the Australian Securities Exchange (“ASX”) under the symbol “AVR.”

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd (ASX: AVR) is a structural heart company committed to designing, developing, and commercializing innovative medical devices. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is science-driven, with an experienced team of multidisciplinary professionals delivering potentially transformative solutions to structural heart disease patients.

Anteris’ lead product, DurAVR^®, is a transcatheter heart valve for treating aortic stenosis. It is the first transcatheter aortic valve replacement to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.

DurAVR^® THV is made using ADAPT^® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT^® tissue has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide.

The ComASUR^® Delivery System was designed to provide controlled deployment and accurate placement of the DurAVR^® THV with balloon-expandable delivery, designed to achieve precise alignment with the heart’s native commissures to achieve ideal valve positioning.

Note: Net loss and revenue are in U.S. dollars for the 12 months that ended Sept. 30, 2024.

(Note: Anteris Technologies Global priced its public offering/NASDAQ uplisting at $6.00 – below the proposed reference price of $6.78 – and priced 14.8 million shares – the same number of shares in the prospectus – to raise $88.8 million on Thursday night, Dec. 12, 2024.)